News | July 11, 2025
Pfizer and Astellas' Xtandi combo extends survival in early prostate cancer setting
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%
Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
_256_384.png)
Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI
BDRs journey for the treatment of Prostate Cancer started with Abiratarone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
Study achieves primary endpoint of radiographic progression-free survival
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
